Advertisement
Advertisement

HIV Care Today


Journal Club: In Early HIV Infection, Little Reason to Delay Therapy
By Paul E. Sax, M.D.
January 8, 2012

Over in Journal of Infectious Diseases, the so-called Setpoint study -- a randomized strategy trial -- investigated whether a 36-week period of treatment would delay the need to go on continuous HIV therapy, compared with observation. After 130 of a planned 150 patients were enrolled, a Data Safety Monitoring Board elected to stop the study due to this key finding: "... the higher rate of progression to needing treatment in the Deferred Treatment group (50%) versus the Immediate Treatment (10%) group."

Read more …


No HIV in Pepsi? Now THAT'S a Relief
By Paul E. Sax, M.D.
December 14, 2011

How reassuring to be treated with the following news: "An SMS has been circulating that Pepsi products are contaminated with HIV but Permanis Sandilands Sdn Bhd has clarified that this is a hoax. Its marketing vice-president Hemalatha Ragavan said there was no truth to it. She urged people not to believe such claims." I have a couple of thoughts about this breaking story.

Read more …


A Bad Note in HIV Prevention: Our VOICE May Be Hoarse, but the Opera Isn't Over
By Bethsheba Johnson, G.N.P.-B.C., A.A.H.I.V.S.
November 29, 2011

Another disappointing note was bellowed out this month concerning the discontinuation of part of a significant HIV prevention trial in women. The 1% tenofovir (Viread) gel arm of the VOICE phase 2B clinical trial was halted early by the independent Data and Safety Monitoring Board (DSMB).

Read more …


Under The Radar: Mental Health and HIV Risk
By David Fawcett, Ph.D., L.C.S.W.
November 22, 2011

Getting the level of new infections down to zero will require breakthroughs not only in medications and improved interventions, but also a broadening of our understanding about the underlying causes of high-risk behaviors which can increase vulnerability for HIV, specifically, mental health concerns.

Read more …


Who Should Care for the Aging HIV Patient? Everything Old Is ... Oh You Know
By Paul E. Sax, M.D.
November 21, 2011

Over in Journal Watch AIDS Clinical Care, Carlos Del Rio reviews a couple of remarkable studies on HIV and aging.

Read more …


Testosterone Replacement Therapy and Polycythemia in HIV-Infected Patients
By Nelson Vergel, B.S.Ch.E., M.B.A.
November 16, 2011

A research letter recently published in the journal AIDS by Vorkas et al determined that testosterone use was associated with polycythemia, and intramuscular administration demonstrated a stronger association than topical (testosterone patch) use. No adverse cardiovascular or thrombotic events were observed. HIV-infected patients taking testosterone should undergo routine hematologic monitoring with adjustment of therapy when appropriate.

Read more …


HCV Treatment Studies at AASLD: Wow ... and I Mean WOW!
By Paul E. Sax, M.D.
November 10, 2011

I didn't attend "The Liver Meeting" (the nickname for the annual meeting of the American Association for the Study of Liver Diseases, AASLD), but the studies presented there this week on HCV treatment were absolutely mind-boggling.

Read more …


HIV and Sexual Function in Women Over 50
By Bethsheba Johnson, G.N.P.-B.C., A.A.H.I.V.S.
November 8, 2011

I recently wrote a "stand-up" blog (pun intended) on erectile dysfunction in HIV-positive men over age 50, which caused a few tongues to wag. So in order to present "fair balance" between the genders, this "dictates" (oh my) that I must blog on HIV-positive women over 50 and sexual function, or lack thereof.

Read more …


I Am Tired of Watching Them Cry: Facing the Emotional Burden of HIV Stigma
By Lisa Fitzpatrick, M.D., M.P.H.
October 31, 2011

I was a new provider in the clinic, and she was one of my first patients, HIV positive for over 10 years. As I entered the exam room and saw her staring out the window, I made at least half a dozen intuitive assessments about her. She was well-dressed; clearly a strong and authoritative woman; a well-respected professional with very high standards of herself and others. As she began to share her story, I realized I was correct on all counts. Judging by the questions she asked me, I was not spared from her high expectations.

Read more …


Will An Antiretroviral Patch Help Adherence? Doubtful
By Paul E. Sax, M.D.
October 29, 2011

Preliminary research suggests that a patch could deliver an AIDS drug to patients ... The researchers successfully used transdermal patches to administer 96 percent of an AIDS drug to simulated skin over a week. "Still, the important limitation of pills, regardless of how few there are or even how minimal the side effects, is adherence," Johnston [the investigator] noted. Research has shown that many patients, if not most, don't take their pills all the time.

Read more …

 < Prev  |  1  |  …  |  8  |  9  |  10  |  11  |  12  |  …  |  15  |  Next > 

Get email notifications every time HIV Care Today is updated.



This article was provided by TheBodyPRO.com.
 

Advertisement